Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18749732 | 2,4-DISUBSTITUTED PYRIDINES AS MALODOR COUNTERACTING INGREDIENTS | June 2024 | December 2025 | Abandon | 18 | 2 | 0 | No | No |
| 18521859 | THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSES | November 2023 | October 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18134203 | USE OF [(1R)-1-(2-CHLOROPHENYL)-2-(TETRAZOL-2-YL)ETHYL] CARBAMATE IN COMBINATION THERAPY | April 2023 | March 2026 | Allow | 35 | 1 | 0 | No | No |
| 18245801 | CYCLIN-DEPENDENT KINASE 7 (CDK7) NON-COVALENT INHIBITORS | March 2023 | February 2026 | Allow | 35 | 1 | 0 | No | No |
| 18002476 | INDAZOLE-FUSED CYCLIC COMPOUND | December 2022 | June 2025 | Allow | 30 | 0 | 0 | No | No |
| 18010699 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | December 2022 | March 2026 | Allow | 39 | 1 | 1 | No | No |
| 18007866 | Novel Pharmaceutical Composition Comprising Combination of Olopatadine and Nepafenac | December 2022 | February 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17999189 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SMALL-CELL LUNG CANCER ASSOCIATED WITH RON MUTANTS AND METHOD USING SAME | November 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17932740 | PFD LOADED MICROSPHERES AND METHOD FOR PREPARING INJECTABLE COMPOSITE MICROSPHERE HYDROGEL SOLUTION FROM SAME | September 2022 | August 2025 | Allow | 35 | 4 | 0 | Yes | No |
| 17553211 | Topical Ointment Composition, Methods Of Use, And Methods Of Preparation | December 2021 | April 2024 | Abandon | 28 | 2 | 0 | No | No |
| 17611532 | PRODUCT FOR TREATING KERATINOUS FIBERS, CONTAINING SILANES OF SPECIFIC FORMULAE | November 2021 | November 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17290217 | METHOD FOR TREATING HAIR, COMPRISING THE APPLICATION OF AN ORGANIC SILICON COMPOUND, AN ALKALISING AGENT AND A FILM-FORMING POLYMER | April 2021 | December 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17225309 | TOPICAL INJECTABLE COMPOSITION | April 2021 | June 2024 | Abandon | 38 | 2 | 0 | No | No |
| 17280567 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING FABRY DISEASE, CONTAINING TSP1 PROTEIN INHIBITOR AS ACTIVE INGREDIENT | March 2021 | December 2025 | Abandon | 57 | 2 | 1 | No | No |
| 17274134 | MEDICAL HYDROGEL HAVING RADIATION PROTECTION FUNCTION | March 2021 | November 2025 | Abandon | 57 | 4 | 0 | No | No |
| 17263856 | PHARMACEUTICAL COMPOSITION COMPRISING ELTROMBOPAG OLAMINE | January 2021 | October 2023 | Abandon | 32 | 2 | 0 | No | No |
| 17257827 | METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY | January 2021 | June 2024 | Abandon | 41 | 1 | 0 | No | No |
| 15674613 | TAMPER RESISTANT FORMULATION OF EPHEDRINE AND ITS DERIVATIVES | August 2017 | January 2020 | Abandon | 29 | 1 | 1 | No | No |
| 15431005 | INTRAVAGINAL DRUG DELIVERY DEVICE | February 2017 | March 2020 | Abandon | 37 | 2 | 1 | Yes | No |
| 14702376 | PHARMACEUTICAL ADHESIVE COMPOSITIONS FOR TREATMENT OF EPISTAXIS AND METHODS OF USE THEREOF | May 2015 | April 2020 | Abandon | 59 | 4 | 1 | No | No |
| 13257978 | Medicinal Cream For Diaper Rash And A Process To Make It | January 2012 | July 2013 | Abandon | 22 | 1 | 0 | No | No |
| 13132343 | Solid Dosage Forms Of Bendamustine | September 2011 | June 2013 | Abandon | 25 | 1 | 0 | No | No |
| 13192163 | Method and Composition for Reducing Exhaled Carbon Dioxide Emissions | July 2011 | July 2013 | Abandon | 23 | 1 | 0 | No | No |
| 13066291 | Creatine compositions for skin treatment | April 2011 | March 2014 | Abandon | 35 | 2 | 0 | No | No |
| 12926463 | Extended release composition containing tramadol | November 2010 | May 2012 | Abandon | 18 | 1 | 0 | No | No |
| 12865494 | COMPOSITION FOR EXTERNAL APPLICATION ON SKIN, AND SKIN-WHITENING COSMETIC | July 2010 | August 2012 | Abandon | 24 | 1 | 0 | No | No |
| 12824803 | Bioactive Dose Having a Rapid Release Coating or Rapid Release Layer Containing a Material for Modulating pH of a Bodily Fluid to Help or Hinder Absorption of a Bioactive | June 2010 | March 2012 | Abandon | 21 | 1 | 0 | No | No |
| 12809164 | COATED EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM | June 2010 | June 2012 | Abandon | 24 | 1 | 0 | No | No |
| 12602003 | COSMETIC COMPOSITION FOR SKIN WHITENING COMPRISING THE EXTRACT OF MAGNOLIA SIEBOLDII AS ACTIVE INGREDIENT | November 2009 | July 2012 | Abandon | 31 | 1 | 0 | No | No |
| 12616192 | USE OF S-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS | November 2009 | July 2011 | Abandon | 20 | 1 | 0 | No | No |
| 12583430 | Use of D-ribose for fatigued subjects | August 2009 | May 2012 | Abandon | 33 | 1 | 0 | No | No |
| 12440140 | AGENT FOR PREVENTION OR TREATMENT OF BLOOD GLUCOSE LEVEL ELEVATION | March 2009 | July 2012 | Abandon | 40 | 1 | 1 | No | No |
| 12338912 | SUPPRESSANT OF TOXICITY INDUCED BY CANCER CHEMOTHERAPEUTIC AGENT AND COMPOSITION OF CANCER CHEMOTHERAPEUTIC AGENT CONTAINING THE SAME | December 2008 | April 2011 | Abandon | 28 | 1 | 0 | No | No |
| 12240075 | FARNESYL PROTEIN TRANSFERASE INHIBITOR COMBINATIONS WITH ANTIESTROGEN AGENTS | September 2008 | July 2011 | Abandon | 33 | 2 | 0 | No | No |
| 11792850 | Sabcomeline Alone or Combined with a Mood Stabilising or Antimanic Agent to Treat Bipolar Disorders | August 2008 | June 2011 | Abandon | 48 | 2 | 0 | No | No |
| 10586775 | Retinoic Acid-Containing Antidiabetic Agent | July 2008 | May 2011 | Abandon | 58 | 1 | 0 | No | No |
| 11913798 | Method to Treat and Prevent Posterior Capsule Opacification | February 2008 | October 2014 | Allow | 60 | 4 | 1 | Yes | Yes |
| 12028771 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY | February 2008 | May 2013 | Abandon | 60 | 2 | 1 | No | Yes |
| 11930877 | COMPOSITION CONTAINING PROGESTIN, PHYTOESTROGEN AND ESTROGEN | October 2007 | April 2011 | Abandon | 42 | 1 | 0 | No | No |
| 11931535 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | October 2007 | April 2011 | Abandon | 42 | 1 | 0 | No | No |
| 11931751 | PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND | October 2007 | October 2011 | Abandon | 47 | 1 | 0 | Yes | No |
| 11930697 | COMPOSITION CONTAINING PROGESTIN, PHYTOESTROGEN AND VITAMIN D | October 2007 | April 2011 | Abandon | 42 | 1 | 0 | Yes | No |
| 11931223 | COMPOSITION CONTAINING PROGESTIN, PHYTOESTROGEN, ESTROGEN AND VITAMIN D COMPOUND | October 2007 | September 2011 | Abandon | 46 | 1 | 0 | No | No |
| 11771473 | PREVENTION OF OVARIAN CANCER BY ADMINISTRATION OF PRODUCTS THAT INDUCE BIOLOGICAL EFFECTS IN THE OVARIAN EPITHELIUM | June 2007 | May 2011 | Abandon | 47 | 1 | 0 | No | No |
| 11666354 | Tabletting process | June 2007 | February 2014 | Allow | 60 | 4 | 0 | Yes | No |
| 10548685 | Use of secretin in the treatment of schizophrenia | February 2007 | April 2011 | Abandon | 60 | 1 | 0 | Yes | No |
| 11460741 | SIMETHICONE SOLID ORAL DOSAGE FORM | July 2006 | November 2009 | Allow | 40 | 2 | 1 | Yes | No |
| 11404933 | Methods, apparatuses and computer programs for protecting networks against attacks that use forged messages | April 2006 | October 2009 | Abandon | 42 | 2 | 0 | No | No |
| 11374552 | Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma | March 2006 | July 2011 | Abandon | 60 | 2 | 1 | No | No |
| 10501678 | Pharmaceutical composition and method for treating disorders of the central nervous system | July 2005 | April 2011 | Abandon | 60 | 2 | 1 | No | Yes |
| 10489807 | Materials and methods for treatment of neurological disorders involving overactivation of glutamatergic ionotropic receptors | August 2004 | March 2011 | Abandon | 60 | 4 | 1 | No | No |
| 10924591 | Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning | August 2004 | March 2011 | Abandon | 60 | 2 | 1 | No | No |
| 10813760 | Compositions with reduced hepatotoxicity | March 2004 | August 2011 | Abandon | 60 | 5 | 0 | Yes | Yes |
| 10801986 | Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion | March 2004 | May 2011 | Abandon | 60 | 4 | 1 | No | Yes |
| 10797795 | Carbamate compounds for use in preventing or treating neurodegenerative disorders | March 2004 | July 2011 | Abandon | 60 | 5 | 1 | No | No |
| 10461701 | Method of promoting sleep using topical administration of vasoactive agents | June 2003 | December 2010 | Abandon | 60 | 6 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KWON, YONG SOK.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KWON, YONG SOK works in Art Unit 1613 and has examined 47 patent applications in our dataset. With an allowance rate of 6.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner KWON, YONG SOK's allowance rate of 6.4% places them in the 1% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KWON, YONG SOK receive 1.96 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KWON, YONG SOK is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +37.5% benefit to allowance rate for applications examined by KWON, YONG SOK. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 0.0% of applications are subsequently allowed. This success rate is in the 0% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 22.2% of cases where such amendments are filed. This entry rate is in the 28% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 33.3% of appeals filed. This is in the 4% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.1% of allowed cases (in the 75% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.